AngioDynamics (ANGO) Projected to Post Quarterly Earnings on Tuesday

AngioDynamics (NASDAQ:ANGO) will likely be releasing its Q2 2026 results before the market opens on Tuesday, January 6th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $76.4330 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, January 6, 2026 at 8:00 AM ET.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. The company had revenue of $75.71 million during the quarter, compared to analysts’ expectations of $72.69 million. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.AngioDynamics’s revenue was up 12.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.11) EPS. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AngioDynamics Stock Down 1.2%

NASDAQ:ANGO opened at $12.68 on Friday. AngioDynamics has a twelve month low of $8.27 and a twelve month high of $13.99. The stock’s 50-day simple moving average is $12.67 and its 200 day simple moving average is $10.97. The firm has a market capitalization of $522.42 million, a PE ratio of -16.26 and a beta of 0.47.

Wall Street Analysts Forecast Growth

ANGO has been the topic of several research reports. Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st. Canaccord Genuity Group boosted their target price on shares of AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

Insiders Place Their Bets

In other AngioDynamics news, CEO James C. Clemmer acquired 10,000 shares of AngioDynamics stock in a transaction that occurred on Thursday, October 9th. The shares were bought at an average price of $11.15 per share, with a total value of $111,500.00. Following the completion of the purchase, the chief executive officer directly owned 882,529 shares in the company, valued at $9,840,198.35. This trade represents a 1.15% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Lawrence T. Weiss bought 10,000 shares of the business’s stock in a transaction on Tuesday, October 21st. The shares were bought at an average cost of $11.81 per share, for a total transaction of $118,100.00. Following the completion of the acquisition, the senior vice president directly owned 93,597 shares in the company, valued at approximately $1,105,380.57. This trade represents a 11.96% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 20,890 shares of company stock worth $239,532. 6.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANGO. Armistice Capital LLC boosted its position in shares of AngioDynamics by 7.1% during the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the medical instruments supplier’s stock valued at $18,274,000 after acquiring an additional 108,185 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of AngioDynamics during the third quarter valued at approximately $118,000. Millennium Management LLC boosted its stake in shares of AngioDynamics by 28.1% during the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after purchasing an additional 393,682 shares in the last quarter. Moore Capital Management LP grew its holdings in shares of AngioDynamics by 162.5% during the 3rd quarter. Moore Capital Management LP now owns 237,964 shares of the medical instruments supplier’s stock worth $2,658,000 after acquiring an additional 147,324 shares during the period. Finally, Bank of America Corp DE raised its holdings in AngioDynamics by 20.6% in the third quarter. Bank of America Corp DE now owns 345,290 shares of the medical instruments supplier’s stock worth $3,857,000 after purchasing an additional 59,082 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.